Kisunla (donanemab-azbt) approved by the FDA for the treatment of early symptomatic Alzheimer’s disease – Eli Lilly
The FDA approved Kisunla (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company’s Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease (AD), which… read more.
